NCT04751370 2026-03-18
Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
12 trialsNCT04929028 2026-03-18
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04963283 2026-02-10
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
University of Colorado, Denver
Phase 2 Active not recruiting
NCT04362839 2026-01-28
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
City of Hope Medical Center
Phase 1 Completed
NCT04599140 2026-01-22
SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT03921684 2026-01-05
Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients
Rabin Medical Center
Phase 2 Active not recruiting
NCT04017650 2025-11-20
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT05732389 2025-08-07
RESET-R
Odense University Hospital
Phase 2 Recruiting
NCT03642067 2025-06-15
Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT04503694 2025-03-05
REGINA
Jules Bordet Institute
Phase 2 Recruiting
NCT04124601 2024-04-23
CHINOREC
Medical University of Vienna
Phase 2 Completed
NCT02948348 2021-09-16
Study to Nivolumab Following Preoperative Chemoradiotherapy
National Cancer Center Hospital East
Phase 1/2 Unknown